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Purpose of the study: 
To assess the short- and long-term outcomes of patients undergoing MitraClip for severe MR in the setting of 
cardiogenic shock.  
 
Methods: 
This was a retrospective observational cohort study of patients who underwent MitraClip at large academic 
institution between 2013 and 2019. Charts were reviewed to identify patients with pre-procedure cardiogenic 
shock if at least 1 of the following was present: 1) documentation of ongoing cardiogenic shock by a provider, 
2) cardiac index <2.2 or 3) use of inotropes (Dobutamine, Milrinone or Dopamine) or vasopressors 
(Norepinephrine, Epinephrine or Vasopressin) within 24 hours of the procedure. 
 
Results: 
Out of 448 MitraClip patients, 29 (6.5%) were identified as having pre-procedure cardiogenic shock. Of those 
in cardiogenic shock prior to MitraClip, 26 (90%) were on inotropes and 16 (55%) were on vasopressors. This 
decreased to 22 (76%) and 15 (52%) post-procedure, respectively, though did not reach statistical significance 
(p=0.80). On pre-procedure echocardiography, MR severity was graded as severe or very severe in 21 (72.4%) 
of those with cardiogenic shock and 301 (71.8%) of those without shock. Of these patients, MR severity was 
reduced to moderate or less in 26 (89.7%) of those with shock and 400 (95.5%) of those without shock 
following the procedure (p=0.80). 
 
Conclusion: 
Use of MitralClip for the treatment of MR in the setting of cardiogenic shock is feasibility, with noted 
reductions in the severity of MR and inotropic requirements.  
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